Kura Oncology, a clinical-stage biopharmaceutical company, recently reported promising data from its ongoing Phase 2 clinical trial of its drug candidate, tipifarnib, in patients with relapsed or refractory acute myeloid leukemia (AML). The company also announced that it is expanding the trial enrollment to include additional patients.
AML is a type of blood cancer that affects the bone marrow and blood cells. It is a rapidly progressing disease that can be difficult to treat, especially in patients who have relapsed or are refractory to standard therapies. Tipifarnib is a selective inhibitor of farnesyl transferase, an enzyme that plays a key role in the growth and survival of cancer cells.
The Phase 2 trial of tipifarnib enrolled 59 patients with relapsed or refractory AML who had received at least one prior therapy. The patients were treated with tipifarnib at a dose of 600 mg twice daily for 21 days of a 28-day cycle. The primary endpoint of the trial was overall response rate (ORR), which is the proportion of patients who achieve a complete remission (CR) or a complete remission with incomplete hematologic recovery (CRi).
The data from the trial showed an ORR of 50%, with 30% of patients achieving a CR and 20% achieving a CRi. The median duration of response was 4.6 months, and the median overall survival was 6.5 months. These results are encouraging, especially considering that the patients in the trial had relapsed or refractory disease and had limited treatment options.
Kura Oncology also announced that it is expanding the trial enrollment to include an additional 30 patients. The company believes that tipifarnib has the potential to be an effective treatment option for patients with relapsed or refractory AML, and the expansion of the trial will allow more patients to benefit from the drug.
In addition to the Phase 2 trial in AML, Kura Oncology is also conducting clinical trials of tipifarnib in other types of cancer, including chronic myelomonocytic leukemia (CMML) and peripheral T-cell lymphoma (PTCL). The company is also developing other drug candidates that target specific genetic mutations that drive the growth and survival of cancer cells.
Overall, the promising data from the Phase 2 trial of tipifarnib in AML and the expansion of the trial enrollment are positive developments for Kura Oncology and for patients with relapsed or refractory AML. The company’s focus on developing targeted therapies for specific genetic mutations in cancer cells has the potential to revolutionize cancer treatment and improve outcomes for patients.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- EVM Finance. Unified Interface for Decentralized Finance. Access Here.
- Quantum Media Group. IR/PR Amplified. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence.